Knockdown of clusterin inhibits the growth and migration of renal carcinoma cells and leads to differential gene expression

Shi,Hua; Deng,Jun-Hong; Wang,Zhu; Cao,Kai-Yuan; Zhou,Liang; Wan,Hua

doi:10.3892/mmr.2013.1470

July 2013 Volume 8 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July 2013 Volume 8 Issue 1

Full Size Image

Article

Knockdown of clusterin inhibits the growth and migration of renal carcinoma cells and leads to differential gene expression

Authors:
- Hua Shi
- Jun-Hong Deng
- Zhu Wang
- Kai-Yuan Cao
- Liang Zhou
- Hua Wan
View Affiliations / Copyright

Affiliations: Department of Urology, The First People's Hospital Affiliated to Guangzhou Medical University, Guangzhou 510180, P.R. China, Research Center for Clinical Laboratory Standard, Department of Medical Microbiology, Zhongshan Medical School of Sun Yat-sen University, Guangzhou 510080, P.R. China
Pages: 35-40
|
Published online on: May 10, 2013

https://doi.org/10.3892/mmr.2013.1470
Expand metrics +

Abstract

Clusterin (CLU) is a glycoprotein involved in tumor progression, whose expression level correlates with the metastasis of renal cell carcinoma (RCC). However, the mechanism by which CLU plays an oncogenic role in RCC remains unclear. In this study, we used the human renal cancer cell 786-O as an experimental model. We knocked down CLU expression in the 786-O cells using lentiviral vector-mediated delivery of RNAi, and then compared the gene expression profiles between the knocked down CLU 786-O cells and control cells. We observed that CLU knockdown induced apoptosis and inhibited the proliferation and migration of 786-O cells. Microassay analysis revealed changes in the expression of 588 genes between the 786-O cells infected by a si-CLU lentivirus and the control cells, where 356 genes were upregulated and 232 were downregulated. Pathway analysis classified the differentially expressed genes into 17 upregulated and 12 downregulated pathways, including the PI3K/Akt, MAPK and VEGF pathways. In this study, we demonstrated that CLU acts as an oncogene in RCC by promoting cell proliferation and migration and inhibiting apoptosis. Microassay analysis may provide a platform for further characterization of the individual genes implicated in the development of RCC, providing new insights into the oncogenic role of CLU.

View Figures

View References

1	Patel C, Ahmed A and Ellsworth P: Renal cell carcinoma: a reappraisal. Urol Nurs. 32:182–190. 2012.PubMed/NCBI
2	Cohen HT and McGovern FJ: Renal cell carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
3	Rosenberg ME and Silkensen J: Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol. 27:633–645. 1995. View Article : Google Scholar : PubMed/NCBI
4	Shannan B, Seifert M, Leskov K, et al: Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ. 13:12–19. 2006. View Article : Google Scholar : PubMed/NCBI
5	Busam KJ, Kucukgol D, Eastlake-Wade S, et al: Clusterin expression in primary and metastatic melanoma. J Cutan Pathol. 33:619–623. 2006. View Article : Google Scholar : PubMed/NCBI
6	Bi J, Guo AL, Lai YR, et al: Overexpression of clusterin correlates with tumor progression, metastasis in gastric cancer: a study on tissue microarrays. Neoplasma. 57:191–197. 2010. View Article : Google Scholar : PubMed/NCBI
7	Miyake H, Gleave ME, Arakawa S, et al: Introducing the clusterin gene into human renal cell carcinoma cells enhances their metastatic potential. J Urol. 167:2203–2208. 2002. View Article : Google Scholar : PubMed/NCBI
8	Wei L, Xue T, Wang J, et al: Roles of clusterin in progression, chemoresistance and metastasis of human ovarian cancer. Int J Cancer. 125:791–806. 2009. View Article : Google Scholar : PubMed/NCBI
9	Bai J and Hu S: Transcriptome network analysis reveals potential candidate genes for squamous lung cancer. Int J Mol Med. 29:95–101. 2012.PubMed/NCBI
10	Sakai I, Miyake H, Takenaka A and Fujisawa M: Expression of potential molecular markers in renal cell carcinoma: impact on clinicopathological outcomes in patients undergoing radical nephrectomy. BJU Int. 104:942–946. 2009. View Article : Google Scholar
11	Kususda Y, Miyake H, Gleave ME and Fujisawa M: Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model. Br J Cancer. 106:1945–1952. 2012. View Article : Google Scholar : PubMed/NCBI
12	Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
13	Shaikhibrahim Z, Lindstrot A, Langer B, Buettner R and Wernert N: Comprehensive gene expression microarray analysis of Ets-1 blockade in PC3 prostate cancer cells and correlations with prostate cancer tissues: Insights into genes involved in the metastatic cascade. Int J Mol Med. 27:811–819. 2011.
14	Tabuchi Y, Wada S, Furusawa Y, Ohtsuka K and Kondo T: Gene networks related to the cell death elicited by hyperthermia in human oral squamous cell carcinoma HSC-3 cells. Int J Mol Med. 29:380–386. 2012.PubMed/NCBI
15	Beroukhim R, Brunet JP, Di Napoli A, et al: Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 69:4674–4681. 2009. View Article : Google Scholar : PubMed/NCBI
16	Monzon FA, Alvarez K, Gatalica Z, et al: Detection of chromosomal aberrations in renal tumors: a comparative study of conventional cytogenetics and virtual karyotyping with single-nucleotide polymorphism microarrays. Arch Pathol Lab Med. 133:1917–1922. 2009.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Knockdown of clusterin inhibits the growth and migration of renal carcinoma cells and leads to differential gene expression

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles